Related Experiment Videos
High-risk multiple myeloma treated with high-dose melphalan.
H M Lokhorst1, O J Meuwissen, L F Verdonck
1University Hospital Utrecht, Department of Haematologie, The Netherlands.
Summary
High-dose melphalan (HDM) shows efficacy in untreated multiple myeloma (MM), inducing good remissions. However, toxicity and short remission duration necessitate exploring alternative strategies before recommending HDM as a first-line treatment.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Poor-risk MM patients often have limited treatment options and poor prognoses.
- High-dose melphalan (HDM) is an intensive chemotherapy regimen.
Purpose of the Study:
- To evaluate the efficacy and toxicity of HDM (140 mg/m2) in patients with poor-risk multiple myeloma.
- To assess treatment response, remission duration, and survival in untreated and pretreated MM patients receiving HDM.
Main Methods:
- A cohort of 26 patients with poor-risk multiple myeloma was studied.
- Thirteen patients were previously untreated, and 13 had received prior vincristine, Adriamycin, and dexamethasone (VAD) therapy.
- Efficacy was assessed by response rates, remission duration, and relapse-free period. Toxicity, including myelosuppression and infections, was monitored.
Main Results:
- All 11 fully assessed, untreated patients responded to HDM, with six achieving complete response.
- Remission duration was short (median 16 months), potentially due to unfavorable prognostic factors like high beta 2-microglobulin and plasma cell labeling index.
- Pretreated patients showed limited response, and the relapse-free period was not improved compared to VAD alone. Major complications included severe infections and three toxic deaths.
Conclusions:
- HDM is effective in inducing good remissions in untreated multiple myeloma.
- The short response duration and significant toxicity, including prolonged myelosuppression and severe infections, limit its use.
- Further research into alternative therapeutic strategies is needed to reduce toxicity and prolong remission duration before HDM can be considered a first-line treatment for younger MM patients.